Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OPEN-LUNGS

Financiado

Cerrado

Pulsehaler A Breakthrough Treatment for COPD

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has developed a novel... ver más

28/02/2023

RESPINOVA LTD

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

RESPINOVA LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-02-28

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

RESPINOVA LTD

880.48K€ | Lider

ORMAZABAL PROTECTION AUTOMAT...

343.39K€ | Participante

Proyectos interesantes

STOP-COPD

Medical Technol...

Data Science

3M€ Cerrado

PulseHaler

Medical Technol...

Medical Devices

71K€ Cerrado

TOLIFE

Medical Technol...

Artificial Inte...

6M€ Cerrado

ASTHMAPOC

Medical Technol...

Data Science

71K€ Cerrado

A3BL

Medical Technol...

Data Science

71K€ Cerrado

WELMO

Medical Technol...

Electronics

4M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 24 meses Fecha Inicio: 2021-02-17
Fecha Fin: 2023-02-28

Líder del proyecto

RESPINOVA LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has developed a novel device, called Pulsehaler™, to treat COPD in a revolutionary way by re-opening the small airways which are known to collapse in COPD patients thereby making it increasingly difficult to breathe. No other COPD treatment in the market today can effectively open these airways. In a clinical trial, PulseHaler™ was shown to substantially improve exercise capacity (the strongest predictor of morbidity and mortality), breathing ability, and quality of life of COPD sufferers. If Pulsehaler™ can reduce costs by the same magnitude to which it has been demonstrated to improve patients’ exercise capacity, the current cost burden of COPD in Europe could be reduced by up to €21B annually. We intend to complete several actions in this project which will bring Pulsehaler™ to the commercial market, and allow Respinova to scale up into a world leader in treating respiratory diseases. A multicenter international clinical trial will be conducted to further build data on Pulsehaler efficacy and support marketing launch. We will obtain CE Mark regulatory approval, and proceed to launch the Pulsehaler™ in the market, scaling up sales, marketing, and production. Respinova Ltd. is a SME based in Israel with 12 employees currently. We have a seasoned management team with decades of combined medical device, business and leadership experience. We are a Horizon 2020 SME Phase II SME grant winner, and two-time EIC Seal of Excellence winner, for our Pulsehaler™ technology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores